Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13481172 | 0.85 | RAB9A (0.43) | SMN1; SMN2L3MBTL1NPC1MAPTRAB9A | |
| SCHEMBL15885797 | 0.83 | BRAF (0.46) | SMN1; SMN2L3MBTL1MAPK13CSNK1DCSNK1E | |
| SCHEMBL1554588 | 0.83 | CSNK1D (0.57) | HTR2AKMT2AMAPK13CSNK1DCSNK1E | |
| SCHEMBL4309166 | 0.83 | KEAP1 (0.47) | SMN1; SMN2L3MBTL1NPC1MAPTRAB9A | |
| SCHEMBL3922875 | 0.82 | L3MBTL1 (0.48) | HTR2AL3MBTL1MAPTKMT2AMAPK13 | |
| SCHEMBL4128565 | 0.81 | MAPK13 (0.54) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL13874177 | 0.80 | APP (0.41) | SMN1; SMN2L3MBTL1NPC1MAPTRAB9A | |
| SCHEMBL15885508 | 0.80 | TGFBR1 (0.49) | SMN1; SMN2HTR2AL3MBTL1NPC1MAPT | |
| SCHEMBL13874337 | 0.79 | HTR2A (0.44) | HTR2AMAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL15885979 | 0.79 | CHRNB2 (0.41) | SMN1; SMN2L3MBTL1NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| EP-4504719-A1 | EGFR INHIBITORS | Blueprint Medicines Corporation (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119325471-A | EGFR inhibitors | 缆图药品公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2023196283-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196283-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-3181133-B1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3181133-B1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3181133-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | Pfizer Inc (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181133-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | Pfizer Inc (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2654750-B1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2654750-B1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2654750-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | Pfizer Inc (US) | 2013-10-30 | — | — | EP | disclosed |
| US-8536164-B2 | Fused pyridine compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536164-B2 | Fused pyridine compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536164-B2 | Fused pyridine compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2012085721-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC | 2012-06-21 | — | — | US | disclosed |
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC | 2012-06-21 | — | — | US | disclosed |
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | SMN1; SMN2 4587/4885HTR2A 3976/4885L3MBTL1 4175/4885 |
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | CSNK1A1, CSNK1A1L, CSNK1E | SMN1; SMN2 2431/4885HTR2A 4024/4885L3MBTL1 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.